Our data in ε2 carriers with high levels of soluble, circulating PD‐L1 associating with higher EF scores may indicate that soluble PD‐L1 acts as a decoy receptor blocking the PD‐1/PD‐L1 interaction, much like anti‐PD‐L1 antibodies do in cancer immunotherapy. The gene discussed is CD274; the disease is cancer.